Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension.

In 30 seconds

This randomized, double-blind, multicenter Phase III trial assessed the efficacy and safety of a single-pill combination of valsartan/amlodipine/chlorthalidone in 294 patients with uncontrolled hypertension. The triple therapy group achieved a greater reduction in mean sitting systolic blood pressure (MSSBP) of -22.8 mmHg compared to -16.7 mmHg in the dual therapy group (P < 0.0001).

Key findings

• Triple therapy reduced MSSBP by -22.8 mmHg vs -16.7 mmHg for dual therapy (P < 0.0001).
• Mean sitting diastolic blood pressure reduction was significantly greater with triple therapy (P = 0.0006).
• BP normalization rates were 75.9% for triple therapy vs 54.5% for dual therapy (P < 0.0001).
• The incidence of treatment-emergent adverse events was similar between groups (24.7% vs 21.5%, P = 0.5783).

Why it matters

Effective management of hypertension is crucial to reduce cardiovascular risks. This study demonstrates that a single-pill triple combination can significantly enhance blood pressure control, potentially improving patient adherence and outcomes.